AlloVir, Inc. (ALVR) DCF Valuation

AlloVir, Inc. (ALVR) DCF Valuation

US | Healthcare | Biotechnology | NASDAQ
AlloVir, Inc. (ALVR) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

AlloVir, Inc. (ALVR) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Optimize your time and improve precision with our (ALVR) DCF Calculator! Utilizing up-to-date AlloVir data and customizable assumptions, this tool allows you to forecast, analyze, and value AlloVir, Inc. like a seasoned investor.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .2 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 -100 0 0 0 -25 -25 -25 -25 -25
EBITDA -26.7 -69.7 -169.8 -166.4 -190.1 .0 .0 .0 .0 .0
EBITDA, % -16170.91 100 100 100 100 60 60 60 60 60
Depreciation .0 .1 1.1 2.6 .4 .0 .0 .0 .0 .0
Depreciation, % 11.52 100 100 100 100 82.3 82.3 82.3 82.3 82.3
EBIT -26.7 -69.8 -171.0 -169.0 -190.5 .0 .0 .0 .0 .0
EBIT, % -16182.42 100 100 100 100 60 60 60 60 60
Total Cash 126.1 356.3 248.1 233.8 183.9 .0 .0 .0 .0 .0
Total Cash, percent .1 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .6 .5 .1 .2 .2
Account Receivables, % 339.39 100 100 100 100
Inventories .0 -.5 -.1 -.2 .0 .0 .0 .0 .0 .0
Inventories, % 0 100 100 100 100 80 80 80 80 80
Accounts Payable .6 1.0 8.4 3.0 6.8 .0 .0 .0 .0 .0
Accounts Payable, % 381.82 100 100 100 100 100 100 100 100 100
Capital Expenditure -.3 -.2 .0 .1 .0 .0 .0 .0 .0 .0
Capital Expenditure, % -205.45 100 100 100 100 -20 -20 -20 -20 -20
Tax Rate, % 0.06612646 0.06612646 0.06612646 0.06612646 0.06612646 0.06612646 0.06612646 0.06612646 0.06612646 0.06612646
EBITAT -24.4 -68.4 -172.0 -168.7 -190.4 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -24.6 -67.7 -163.5 -171.4 -186.5 -6.6 .0 .0 .0 .0
WACC, % 6.53 6.64 6.67 6.67 6.67 6.63 6.63 6.63 6.63 6.63
PV UFCF
SUM PV UFCF -6.1
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -6
Net Debt -63
Equity Value 57
Diluted Shares Outstanding, MM 104
Equity Value Per Share 0.54

What You Will Get

  • Real AlloVir Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for AlloVir, Inc. (ALVR).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to AlloVir, Inc. (ALVR).
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on AlloVir, Inc.'s (ALVR) fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for AlloVir, Inc. (ALVR).
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for AlloVir, Inc. (ALVR).

Key Features

  • 🔍 Real-Life ALVR Financials: Pre-filled historical and projected data for AlloVir, Inc. (ALVR).
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate AlloVir’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize AlloVir’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  • Download: Get the pre-built Excel file containing AlloVir, Inc.'s (ALVR) financial data.
  • Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Develop various projections and instantly compare the results.
  • Make Decisions: Leverage the valuation outcomes to inform your investment strategy.

Why Choose This Calculator for AlloVir, Inc. (ALVR)?

  • Comprehensive Tool: Features DCF, WACC, and financial ratio analyses all in one solution.
  • Customizable Inputs: Modify the yellow-highlighted cells to explore different scenarios.
  • Detailed Insights: Automatically computes AlloVir’s intrinsic value and Net Present Value.
  • Preloaded Data: Historical and projected data provide reliable starting points.
  • Professional Quality: Perfect for financial analysts, investors, and business consultants.

Who Should Use AlloVir, Inc. (ALVR)?

  • Investors: Gain insights into cutting-edge therapies and make informed investment choices.
  • Healthcare Analysts: Utilize comprehensive data to evaluate the potential of innovative treatments.
  • Consultants: Tailor presentations or reports swiftly using AlloVir's latest research and developments.
  • Biotech Enthusiasts: Enhance your knowledge of viral therapies and their market implications through real-world case studies.
  • Educators and Students: Leverage AlloVir's resources as a practical tool in biotechnology and healthcare courses.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled AlloVir, Inc. (ALVR) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for AlloVir, Inc. (ALVR).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.